Buscar resultados de ensayos clínicos

Patrocinado por

Carcinoma, Pancreatic Ductal - 23 Studies Found

Estado Estudiar
Completed Nombre del estudio: Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Condición: Carcinoma, Pancreatic Ductal
Fecha: 2007-05-07
Intervenciones:
  • Drug: AG-013736 oral administr
Completed Nombre del estudio: According CTC to Compare the Influences of Different Methods to Remove the PDAC
Condición:
  • Carcinoma, Pancreatic Ductal
  • Circulating Tumor Cells

Fecha: 2015-05-14
Intervenciones:
  • Procedure: routine surgery To

Terminated Nombre del estudio: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
Condición:
  • Resectable Pancreatic Cancer
  • Pancreatic Ductal Carcinoma
    • <
    Fecha: 2014-09-15
    Intervenciones:
    • Drug: FOLFIRINOX
    • Drug: Gemcitabine/nab-Pac
Completed Nombre del estudio: Continuous Monitoring on the General Ward
Condición:
  • Carcinoma, Pancreatic Ductal
  • Colorectal Neoplasms
  • Fecha: 2016-07-25
    Intervenciones:
    • Device: HealthPatch The Health
Terminated Nombre del estudio: Amatuximab for High Mesothelin Cancers
Condición:
  • Carcinoma, Pancreatic Ductal
  • Mesothelioma
  • Diabetes Mellitus, Adult-Onset
  • Diabetes Complications
  • Fecha: 2015-05-25
Active, not recruiting Nombre del estudio: Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
Condición: Metastatic Pancreatic Ductal Adenocarcinoma
Fecha: 2015-10-20
Intervenciones:
  • Drug: MEDI4736 in combination with nab-paclitaxel and gemcitabine

Active, not recruiting Nombre del estudio: Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Condición: Metastatic Pancreatic Ductal Adenocarcinoma
Fecha: 2015-08-27
Intervenciones:
  • Drug: MEDI4736 monotherapy MED
Completed Nombre del estudio: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Condición: Pancreatic Ductal Adenocarcinoma
Fecha: 2012-04-13
Intervenciones: Drug: INNO-206 INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administ
Enrolling by invitation Nombre del estudio: Clinical Trial of Pancreatic Cancer in Stockholm.
Condición: Pancreatic Cancer
Fecha: 2014-06-11
Intervenciones: Procedure: Pancreatic Surgery Surgical removal of the pancreatic tumour (cancer) in the intervention gro
<<< Previous | Next >>>